Corline Biomedical AB

Stockholm Stock Exchange CLBIO.ST

Corline Biomedical AB Price to Sales Ratio (P/S) on January 14, 2025: 8.30

Corline Biomedical AB Price to Sales Ratio (P/S) is 8.30 on January 14, 2025, a -43.40% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Corline Biomedical AB 52-week high Price to Sales Ratio (P/S) is 14.67 on January 31, 2024, which is 76.72% above the current Price to Sales Ratio (P/S).
Corline Biomedical AB 52-week low Price to Sales Ratio (P/S) is 5.55 on November 28, 2024, which is -33.21% below the current Price to Sales Ratio (P/S).
Corline Biomedical AB average Price to Sales Ratio (P/S) for the last 52 weeks is 10.03.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Stockholm Stock Exchange: CLBIO.ST

Corline Biomedical AB

CEO	Dr. Henrik Nittmar Ph.D.
IPO Date	June 3, 2015
Location	Sweden
Headquarters	Lefflersgatan 5
Employees	13
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; CHC, which is used for the treatment of soft tissue injuries; medical devices; and CHS, a coronary stent. The company was founded in 1991 and is based in Uppsala, Sweden.

Key trends

Past 5 years